HFM
VRTX icon

Hartford Funds Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Hartford Funds Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.39M Buy
3,101
+28
+0.9% +$13.1K 0.12% 47
2025
Q4 		$1.39M Buy
3,073
+1,512
+97% +$652K 0.11% 42
2025
Q3 		$612K Sell
1,561
-193
-11% -$80.7K 0.05% 77
2025
Q2 		$782K Buy
1,754
+394
+29% +$182K 0.07% 66
2025
Q1 		$659K Buy
1,360
+239
+21% +$111K 0.06% 75
2024
Q4 		$451K Buy
1,121
+46
+4% +$21.3K 0.04% 89
2024
Q3 		$500K Buy
1,075
+42
+4% +$20.2K 0.05% 81
2024
Q2 		$484K Buy
1,033
+58
+6% +$25.2K 0.05% 77
2024
Q1 		$407K Buy
975
+85
+10% +$35.9K 0.04% 79
2023
Q4 		$362K Buy
890
+64
+8% +$23.6K 0.04% 76
2023
Q3 		$287K Buy
826
+53
+7% +$18.5K 0.03% 74
2023
Q2 		$272K Buy
773
+107
+16% +$36.1K 0.03% 80
2023
Q1 		$210K Buy
+666
New +$200K 0.02% 84

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Hartford Funds Management's VRTX Position: Q1 2026 in Review

Hartford Funds Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.91% in Q1 2026, buying an estimated $13.1K and bringing the position to 3,101 shares worth $1.39M. The position accounts for 0.12% of the portfolio, ranked #47.

Hartford Funds Management first reported a position in VRTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.39M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Hartford Funds Management held 3,101 shares of Vertex Pharmaceuticals worth $1.39M as of Q1 2026.
  • Hartford Funds Management bought 28 Vertex Pharmaceuticals shares in Q1 2026, an estimated $13.1K.
  • Vertex Pharmaceuticals made up 0.12% of Hartford Funds Management's portfolio in Q1 2026, its #47 holding.
  • Hartford Funds Management first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Hartford Funds Management's Vertex Pharmaceuticals position peaked at $1.39M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Hartford Funds Management's 13F filing for Q1 2026, filed 4 May 2026.